Tacoma, WA – Revalesio Corporation presented data from a Phase I clinical trial related to the use of RNS60 as a novel anti-inflammatory drug at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) in San Diego on February 28 – March 4.

AAAAI is the largest professional organization in the United States devoted to the specialty of allergy and immunology. It has nearly 6,500 members in the United States, Canada and 60 other countries.

The poster presented by Revalesio was titled “A Phase I Assessment of Safety and Tolerability of RNS60, a Novel Therapeutic Containing Charge-stabilized Nanostructures in Asthma” and demonstrated that RNS60 proved to be safe and well tolerated when nebulized alone or together with budesonide. Additionally, the study provided evidence that the combination of RNS60 with a low dose of budesonide may be as effective and safe as the treatment with a higher dose of budesonide. An academic publication is in preparation for submission later in 2014.

Results from this human study suggest that Revalesio’s novel therapeutic RNS60 provides an opportunity for the development of a new generation of low-risk therapeutics for inflammatory pulmonary diseases and combination products.